Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

TAK-079

- PMLiVE

Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies

Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis

- PMLiVE

Takeda’s new study data for oveporexton shows improvements in narcolepsy type 1

The phase 3 results show improvements in daily function, cognition and nighttime sleep

- PMLiVE

Takeda’s zasocitinib demonstrates positive results in plaque psoriasis

Around 64 million people worldwide live with psoriasis

- PMLiVE

Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m

The deal focuses on T cell-based therapies for autoimmune disease

- PMLiVE

BMS, Takeda and Astex join AI training consortium

The initiative focuses on training AI models to aid in drug discovery and development

- PMLiVE

AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

Around 700,000 people in the US are living with some form of the autoimmune disease

- PMLiVE

BMS and Bain Capital launch new company to develop immunology therapies

The newly formed company has in-licensed five investigational immunology drugs from BMS

- PMLiVE

AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

- PMLiVE

Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

- PMLiVE

Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP

The enzyme replacement therapy is now the first treatment approved in the UK for this patient population

- PMLiVE

Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

- PMLiVE

Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m

The B cell depletion therapy has the potential to reach patients earlier in their treatment journeys

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links